8-K: Boston Scientific Exceeds Q4 Adjusted EPS, Drives Strong 2025 Growth

Boston Scientific reports robust fourth quarter and full year 2025 financial results, surpassing adjusted EPS guidance and announcing strategic acquisitions.

Summary

• Boston Scientific generated net sales of $5.286 billion in Q4 2025, a 15.9% reported increase, 14.3% operational, and 12.7% organic growth year-over-year.
• Q4 2025 GAAP net income attributable to common stockholders was $672 million, or $0.45 per share, compared to $566 million or $0.38 per share a year ago.
• Adjusted EPS for Q4 2025 reached $0.80, up from $0.70 a year ago.
• For the full year 2025, net sales were $20.074 billion, growing 19.9% reported, 19.2% operational, and 15.8% organic.
• Full year 2025 GAAP net income attributable to common stockholders was $2.898 billion, or $1.94 per share, compared to $1.853 billion or $1.25 per share in 2024.
• Full year 2025 adjusted EPS was $3.06, up from $2.51 in 2024.
• Cardiovascular segment sales grew 18.2% reported and 16.1% organic in Q4 2025, while MedSurg grew 11.7% reported and 6.5% organic.
• U.S. sales increased 17.0% reported and operational in Q4 2025.
• The company received U.S. FDA approval and CE mark for the FARAPOINT Pulsed Field Ablation (PFA) Catheter.
• Enrollment commenced in the OPTIMIZE clinical trial and the MOSAIC study, and completed in the SIMPLAAFY and FRACTURE IDE clinical trials.
• U.S. launch of the SEISMIQ Intravascular Lithotripsy (IVL) System was initiated.
• Agreements were announced to acquire Penumbra, Inc. and Valencia Technologies Corporation, and the acquisition of Nalu Medical, Inc. was completed.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by robust sales growth, an adjusted EPS beat, and strategic portfolio expansion through acquisitions and new product approvals. The positive outlook for 2026 further reinforces confidence, despite a slight miss on GAAP EPS.

Positives

• Q4 2025 net sales growth of 15.9% reported and 12.7% organic was within the company's guidance range.
• Q4 2025 adjusted EPS of $0.80 exceeded the company's guidance range of $0.77 to $0.79.
• Full year 2025 saw strong reported net sales growth of 19.9% and adjusted EPS growth to $3.06 from $2.51.
• Significant product innovation with FDA approval and CE mark for FARAPOINT PFA Catheter, and FDA 510(k) clearance for TheraSphere 360 Y-90 Management Platform.
• Strategic acquisitions of Nalu Medical completed, and agreements to acquire Penumbra and Valencia Technologies announced, expanding the product portfolio.
• Positive coverage decisions for Intracept Procedure and Endoscopic Sleeve Gastroplasty (ESG) by major health insurers, expanding patient access.

Negatives

• Q4 2025 GAAP EPS of $0.45 was below the company's guidance range of $0.48 to $0.52 per share.
• Management made a decision in Q2 2025 to discontinue worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems, which had prior year global sales of approximately $50 million per quarter.

Risks

• Economic conditions, including the impact of foreign currency fluctuations.
• Future U.S. and global political, competitive, reimbursement, and regulatory conditions, including changing trade and tariff policies.
• Geopolitical events and tensions.
• Manufacturing, distribution, and supply chain disruptions and cost increases.
• Disruptions caused by cybersecurity events.
• Disruptions caused by public health emergencies or extreme weather or other climate change-related events.
• Labor shortages and increases in labor costs.
• Variations in outcomes of ongoing and future clinical trials and market studies.
• New product introductions.
• Expected procedural volumes.
• The closing and integration of acquisitions.
• Demographic trends.
• Intellectual property.
• Litigation.
• Financial market conditions.
• The execution and effect of business strategy, including cost-savings and growth initiatives.
• Future business decisions made by the company and its competitors.

Future Outlook

The company estimates full year 2026 net sales growth to be approximately 10.5% to 11.5% on a reported basis and 10.0% to 11.0% on an organic basis. Full year 2026 adjusted EPS is estimated to be $3.43 to $3.49. For the first quarter of 2026, net sales growth is projected at 10.5% to 12.0% reported and 8.5% to 10.0% organic, with adjusted EPS estimated at $0.78 to $0.80.

Management Comments

• "2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance that enabled us to exceed our goals."
• "As a direct result of the dedication, consistency and winning spirit of our team, we have impacted millions of patient lives and are well-positioned to continue on our strong growth trajectory well into the future."

Industry Context

StockSavvy.ai notes that Boston Scientific's strong performance reflects a robust medical technology market, particularly in cardiovascular and minimally invasive procedures. The strategic acquisitions of Penumbra, Valencia Technologies, and Nalu Medical indicate a clear focus on expanding high-growth segments like thrombectomy, neurovascular solutions, and neuromodulation, aligning with broader industry trends towards specialized, less invasive therapies and digital health platforms.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, exceeding adjusted EPS guidance, and a positive outlook for 2026, potentially leading to increased share value.
• Customers (Healthcare Providers): Enhanced product portfolio with new approvals (FARAPOINT PFA Catheter, TheraSphere 360 Y-90 Management Platform) and launches (SEISMIQ IVL System, Intracept EDGE J Stylet), offering advanced treatment options.
• Patients: Expanded access to innovative, less invasive therapies through new product approvals, clinical trial advancements, and positive insurance coverage decisions (e.g., ESG, Intracept Procedure).
• Employees: Continued growth and strategic acquisitions may lead to expanded opportunities and stability within the company, though restructuring related to discontinued products could impact some roles.
• Competitors: Boston Scientific's aggressive M&A strategy and strong R&D pipeline indicate increased competitive pressure in key medical device segments.

Next Steps

• Boston Scientific management will discuss these results with analysts on a conference call on February 4, 2026, at 8:00 a.m. ET.
• The company will continue to integrate recently acquired businesses like Nalu Medical, Inc. and work towards closing the announced acquisitions of Penumbra, Inc. and Valencia Technologies Corporation.
• Ongoing clinical trials (OPTIMIZE, MOSAIC) will continue enrollment and data collection.
• Further commercialization and market penetration for newly launched products like the SEISMIQ IVL System and Intracept EDGE J Stylet.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with strong revenue growth and an adjusted EPS beat, indicating robust operational execution. Strategic acquisitions and a pipeline of innovative product approvals and launches position Boston Scientific for continued market leadership and expansion into high-growth segments. The positive outlook for 2026 further reinforces the company's strong trajectory, making it an attractive investment for long-term growth.

Keywords

Medical Devices, Cardiovascular, MedSurg, Neuromodulation, Electrophysiology, Urology, Endoscopy, Pulsed Field Ablation, Intravascular Lithotripsy, SEC Filing, Earnings Report, Acquisitions, FDA Approval, CE Mark